Results of Annual General Meeting and General Meeting
June 14 2023 - 8:30AM
Biodexa Pharmaceuticals PLC
(“Biodexa” or the “Company”)
Results of Annual General Meeting and General
Meeting
Biodexa Pharmaceuticals PLC (“Biodexa” or the
“Company”) (NASDAQ: BDRX), a clinical stage biopharmaceutical
company developing a pipeline of products aimed at primary and
metastatic cancers of the brain, announces that at its Annual
General Meeting and subsequent General Meeting held earlier today,
all resolutions put to the Company’s shareholders were duly
passed.
The full text of, inter alia, the resolutions
proposed and passed at the Annual General Meeting and General
Meeting can be found in the Notices of the Annual General Meeting
and General Meeting on the Company's website
at:https://biodexapharma.com/investors/corporate-governance//#company-informationFor
more information, please contact:
Biodexa Pharmaceuticals PLC |
Stephen Stamp, CEO, CFO |
Tel:
+44 (0)29 2048 0180 |
www.biodexapharma.com |
|
Edison Group
(US Investor Relations)Alyssa FactorTel: +1 (860) 573
9637Email: afactor@edisongroup.com |
|
|
|
About Biodexa Pharmaceuticals PLC
Biodexa Pharmaceuticals PLC (listed on NASDAQ:
BDRX) is a clinical stage biopharmaceutical company developing a
pipeline of products aimed at primary and metastatic cancers of the
brain. The Company’s lead candidate, MTX110, is being studied
in aggressive rare/orphan brain cancer indications including
recurrent glioblastoma and diffuse midline glioma.
MTX110 is a liquid formulation of the histone
deacetylase (HDAC) inhibitor, panobinostat. This proprietary
formulation enables delivery of the product via convection-enhanced
delivery (CED) at potentially chemotherapeutic doses directly to
the site of the tumour, by-passing the blood-brain barrier and
avoiding systemic toxicity.
Biodexa is supported by three proprietary drug
delivery technologies focused on improving the bio-delivery and
bio-distribution of medicines. Biodexa’s headquarters and
R&D facility is in Cardiff, UK. For more information
visit www.biodexapharma.com.
Forward-Looking Statements
Certain statements in this announcement may
constitute “forward-looking statements” within the meaning of
legislation in the United Kingdom and/or United States. Such
statements are made pursuant to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995 and are based on
management’s belief or interpretation. All statements
contained in this announcement that do not relate to matters of
historical fact should be considered forward-looking
statements.
Reference should be made to those documents that
Biodexa shall file from time to time or announcements that may be
made by Biodexa in accordance with the rules and regulations
promulgated by the SEC, which contain and identify other important
factors that could cause actual results to differ materially from
those contained in any projections or forward-looking
statements. These forward-looking statements speak only as of
the date of this announcement. All subsequent written and
oral forward-looking statements by or concerning Biodexa are
expressly qualified in their entirety by the cautionary statements
above. Except as may be required under relevant laws in the
United States, Biodexa does not undertake any obligation to
publicly update or revise any forward-looking statements because of
new information, future events or events otherwise arising.
Biodexa Pharmaceuticals (NASDAQ:BDRX)
Historical Stock Chart
From Apr 2024 to May 2024
Biodexa Pharmaceuticals (NASDAQ:BDRX)
Historical Stock Chart
From May 2023 to May 2024